Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Markku Jalkanen
Job: Founder and CEO of the biopharmaceutical company Faron Pharmaceuticals.
Education: Doctor of Biochemistry, University of Turku 1982.
Other: The anticancer drug Clevegen is also in clinical trials. The company’s third drug, which is awaiting a patent and will also have an impact on the regulation of the human defense system, will also be announced this year.
THE development of medicine in Finland requires patience and determination, Jalkanen says.
- Medical research in Finland is of an exceptionally high standard. We also have a significant number of foundations supporting research, but no one builds drug development companies out of research. Finland does not believe that originator medicines could be developed here. It's a pity.
However, Jalkanen decided to establish his company in Finland, even though he and his wife, cancer researcher and academician Sirpa Jalkanen, have also had careers in the United States.
- Faro was founded in 2007. If we had American resources at our disposal during this time, we would be much further now. However, we once came to Finland from California because we did not want the children to become Americans, Jalkanen says.
The legs have three adult children and all work in the medical field.
- They have not been pushed into the industry, but everyone has also seen a lot of frustration and disappointments at home. Understanding often happens through mistakes, Jalkanen says.
THE BEST THING ABOUT DEVELOPMENT WORK, in addition to helping people, is that you get to work with smart and independent people.
- It is challenging to get them to work in the same direction, but when explaining to experts what is being done, they do not need to be motivated separately. It is very rewarding, Jalkanen says.
Jalkanen himself says that he has been really interested in human biology since he was young.
- Understanding the human regulatory system is so interesting that I could not think of anything else.
ALTHOUGH bringing Traumakine to market was, in a way, the biggest achievement of Jalkanen's career, he has no intention of slowing down even after that.
- compared to the leaders in US I'm young. It is a European matter to ask about retirement. Personally, I am not a person who would feel comfortable doing nothing, Jalkanen says.
The Turku-based biopharmaceutical company Turku has experienced exceptionally interesting times this year. The company’s ten-year-old drug, Traumakine, was selected in the spring as part of the World Health Organisation’s (WHO) SOLIDARY study, which looks for ways to improve the chances of survival for covid-19 patients. In addition, the drug is involved in two other studies.
Traumakine was originally developed to treat ARDS in lung disease. Although Traumakine has been at the top of the list of Faro's CEO Markku Jalkanen for years, the corona epidemic suddenly made the drug more topical than expected.
If the WHO study is successful, Traumakine can get a marketing authorization quickly. It is currently known that the traumatic drug interferon-beta and the antiviral remdesivir are no longer included in the study. More information will come at any time.
FOR Jalkanen, bringing the drug to market would be the culmination of a decade of work. In 2018, Traumakine had already entered the phase three research phase and the company was confident that it would work. However, in the study, Traumakine appeared ineffective. It was found that Traumakine was not effective in patients who were also being treated with corticosteroids such as cortisone at the same time. Now patients receiving cortisone have been considered separately in the study, and Jalkanen believes that evidence of the drug's effectiveness will soon be obtained.
- When Traumakine's development began, we had a couple of people involved. Now the company has 30 employees. I already know that I will offer champagnes to the whole group when the sales permit comes, Jalkanen says.
The Turku-based biopharmaceutical company Turku has experienced exceptionally interesting times this year. The company’s ten-year-old drug, Traumakine, was selected in the spring as part of the World Health Organisation’s (WHO) SOLIDARY study, which looks for ways to improve the chances of survival for covid-19 patients. In addition, the drug is involved in two other studies.
Blurb under photo says :
Stop. Forced by Korona, Jalkanen has also had to stop. "One third of my working time has been spent on a plane. I had already forgotten how beautiful the Finnish summer is.
Can't read the rest as you have to subscribe
Lets hope he hasn't spend the whole summer in the backgarden with a hankie tied on his head asleep in a deckchair
HAlti,
What does that translate to ? :-)
14.8.2020
Tj Markku Jalkanen
WHO
https://www.mediuutiset.fi/uutiset/markku-jalkanen-on-naina-paivina-tulisilla-hiililla/2d1c4048-7ff3-4cd8-b40c-3389887f3d2a
Good
This rise look gud I think this will be gud day for this
S*it some of that made no sense, back to sleep!
Reporting from the trials is outside of Farons control, eg. Remap and Solidarity.
What I find strange is that we were promised an update on the new state of the art expansion of interferon for future dispatch to a manufacturer. I would of thought that manufacturing discussions are taking place.
We then have the update or initiation of the Hibiscus trial funded by a third party starting by the end of September.
We can also expect an update on Clevergen which is the real game changer.
With the share price fluctuating until then, in very much the same way that SNG did but it’s transformational news, all we can do is sit and wait. I would of thought that most have now be positioned according to their desired level of risk.
It hasn’t taken much volume to send the share price in either direction, but I think it’s fair to say that interferon has a role to play in the fight against covid. Much depends on the point of treatment during the cycle and hopefully the way in which it is administered.
Yesterday’s WHO update was more about donation/funding than providing physical updates on progress. That was extremely frustrating, however to update on progress before the event runs the risk of further miss reporting on social media and other news streams.
@OilMan, I guess you are right. However, there might be another issue too with the Solidarity trial, stopped arms. I went through the available information and not everything on Solidarity continuing is explained by WHO. However, I think their monitoring committee protocols are known by big pharma and major investment banks.
There are some facts. First of all, Faron's core team has to publish a defensive article IV vs subcutaneos use of IFN-B. In the other hand, they have'nt published any defensive news or plan, any speculative promise. It seems they stand strong. For me, they have at least plan B on the table. Funding is granted, scientific proof is supporting them clearly. SP may drop, but they do not have to rush getting an average deal. Cards are played well.
Company might become a multibagger with high probability. Waiting time is short (1d to 10 months from now). Keep investment size in realistic risk tolerance level, sit and wait.
I wonder if the delay is due to a Takeover V Partner deal...... We have the patent protected!
This is surely worth a significant amount in the current climate. Any suggestions?
U did make the right decision zen
My faith was strong but it is now even stronger because Zen is back. Good days can't be far now, can they?
https://www.youtube.com/watch?v=0l92Ndt6hg8&feature=youtu.be
Absolutely right! When the time is right we shall hear "ihme kanauutisia" from Turku!
TSTfin -
Voidaan toivoa niin? Ihme kanauutisia, jotka tulevat laskemaan.
Naz tell us Volume of 11345! If you download the daily CSV Excel spreadsheet the cumulative total for daily trading is 17992! So a slight discrepancy. Lago have offloaded 2847 shares today. So just over 2k shares in their float for tomorrows trading on Naz.
Se on tapahtumassa:D
Welcome back Zen , with your ÂŁ10 and my hat theres all to play for my friend .
- 5k Shares bought at 14.48pm (Uk Time)
- Lago started offloading at 14:53 (Uk Time)
I often wondered whether LAGO were stockpiling for when news lands! Obviously not, they have no shares!
I didn't think he was getting the Alps chalet until we had hit the magic ÂŁ10 a share. May be this month?